NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
Eisai Inc.
OHSU Knight Cancer Institute
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
University of Birmingham